<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820908</url>
  </required_header>
  <id_info>
    <org_study_id>5792-18 - SMC</org_study_id>
    <nct_id>NCT03820908</nct_id>
  </id_info>
  <brief_title>Bisantrene for Relapsed /Refractory AML</brief_title>
  <official_title>Bisantrene for Relapsed /Refractory Acute Myelogenous Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Race Oncology Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of response in patients with AML that are either primary resistant (failed&#xD;
      induction and or salvage therapy) or relapsed including post allogeneic stem cell&#xD;
      transplantation and failed salvage therapy or cannot receive additional anthracycline .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Actual">July 22, 2020</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The patientswith Rel /Ref AML will receive bisantrene in conjunction with the conventional supportive care. In the event of a CR, patients will receive a 3-day consolidation course of bisantrene 250mg/m2/d (optional).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival will be calculated from the day of bisantrene administration until death or last follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Leukemia-free survival will be calculated from the day of bisantrene administration until relapse, death of any cause, or last follow-up.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Bisantrene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive bisantrene 250mg/m2/d for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisantrene</intervention_name>
    <description>The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.</description>
    <arm_group_label>Bisantrene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must meet all of the following inclusion criteria to be eligible to enroll in&#xD;
             this study.&#xD;
&#xD;
        Disease-related:&#xD;
&#xD;
          1. Patients with Rel/Ref/AML&#xD;
&#xD;
          2. Adequate birth control in fertile patients.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
        Demographic:&#xD;
&#xD;
          1. Age ≥ 18 years and willing and able to comply with the protocol requirements&#xD;
&#xD;
          2. Life expectancy ≥ 3 months Ethical/Other&#xD;
&#xD;
          3. Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
          4. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and&#xD;
             to practice contraception.&#xD;
&#xD;
          5. Male subjects must agree to practice contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease-related&#xD;
&#xD;
               1. Patients with other type of basic disease other than Rel/Ref AML.&#xD;
&#xD;
               2. Patients with respiratory failure (DLCO &lt; 30%).&#xD;
&#xD;
               3. Patients with active congestive heart failure (New York Heart Association [NYHA]&#xD;
                  Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled&#xD;
                  by conventional intervention.&#xD;
&#xD;
               4. Patients with &gt; grade II liver renal toxicity.&#xD;
&#xD;
               5. Psychiatric conditions/disease that impair the ability to give informed consent&#xD;
                  or to adequately co-operate&#xD;
&#xD;
               6. Bilirubin &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit&#xD;
&#xD;
               7. Creatinine &gt; 2.0 mg/dl&#xD;
&#xD;
               8. ECOG-Performance status &gt; 2&#xD;
&#xD;
               9. CNS disease involvement&#xD;
&#xD;
              10. Severe pleural effusion and ascites. Concurrent Conditions&#xD;
&#xD;
               1. Pregnant or lactating females&#xD;
&#xD;
               2. Known human immunodeficiency virus infection&#xD;
&#xD;
               3. Active hepatitis B or C infection&#xD;
&#xD;
               4. Non hematologic malignancy within the past 3 years with the exception of a)&#xD;
                  adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid&#xD;
                  cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of&#xD;
                  Gleason Grade 6 or less with stable prostate-specific antigen levels; or d)&#xD;
                  cancer considered cured by surgical resection or unlikely to impact survival&#xD;
                  during the duration of the study, such as localized transitional cell carcinoma&#xD;
                  of the bladder or benign tumors of the adrenal or pancreas&#xD;
&#xD;
               5. Contraindication to any of the required concomitant drugs or supportive&#xD;
                  treatments, including hypersensitivity to all anticoagulation and antiplatelet&#xD;
                  options, antiviral drugs, or intolerance to hydration due to preexisting&#xD;
                  pulmonary or cardiac impairment&#xD;
&#xD;
               6. Any other clinically significant medical disease or condition that, in the&#xD;
                  Investigator's opinion, may interfere with protocol adherence or a subject's&#xD;
                  ability to give informed consent.&#xD;
&#xD;
               7. Patients with relapse or disease progression &gt;3 months post HSCT are allowed into&#xD;
                  the study unless they have severe (grade III-IV) GVHD.&#xD;
&#xD;
        Patients with grade III-IV GVHD will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>57261</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof Arnon Nagler</investigator_full_name>
    <investigator_title>Arnon Nagler, M.D., M.Sc Professor of Medicine Tel Aviv University, Director Hematology Division BMT and Cord Blood Bank, Chair Israeli BMT Association, Chair of the ALWP of the EBMT, Co-Chair Scientific Council of the EBMT</investigator_title>
  </responsible_party>
  <keyword>relapsed AML</keyword>
  <keyword>refractory AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisantrene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

